Y. Drolet

Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients.

L. Marpeau, A. de Gramont, C. Louvet, 1989, European journal of cancer & clinical oncology.

[Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].

C. Dray, A. de Gramont, C. Louvet, 1986, Journal de gynecologie, obstetrique et biologie de la reproduction.

Adriamycin and cis-platinum in advanced ovarian cancer.

A. de Gramont, Y. Drolet, A. Lavoie, 1985, European Journal of Cancer and Clinical Oncology.

Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma.

E. Raymond, S. Faivre, L. Marpeau, 1997, European journal of obstetrics, gynecology, and reproductive biology.

Erythrocyte mean corpuscular volume during cytotoxic therapy and the risk of secondary leukemia

A. de Gramont, J. Delage, Y. Drolet, 1985, Cancer.

Erythrocyte mean corpuscular volume during cytotoxic therapy is a predictive parameter of secondary leukemia in Hodgkin's disease

M. Boiron, A. de Gramont, C. Louvet, 1987, Cancer.

[Prognosis in ovarian cancer as a function of the results of the second-look laparatomy].

L. Marpeau, A. de Gramont, C. Louvet, 1989, Journal de gynecologie, obstetrique et biologie de la reproduction.

Preleukemic changes in cases of nonlymphocytic leukemia secondary to cytotoxic therapy analysis of 105 cases

M. Boiron, A. de Gramont, C. Louvet, 1986, Cancer.

Study of erythrocyte mean corpuscular volume during cytotoxic therapy as a predictive parameter of the risk of secondary leukemia in Hodgkin's disease.

A. de Gramont, J. Delâge, Y. Drolet, 1984, Cancer treatment reports.

Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.

J. Roy, C. Labrie, M. Pollak, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.